• Strategic Collaboration Agreement signed with the Commonwealth Government funded Pork Cooperative Research Centre
• Agreement connects Anatara with key industry partners in the pork industry
• Agreement opens important international industry ties, including the USA
• No additional funds required from Anatara
BRISBANE, 11th August 2015: Anatara Lifesciences (ASX:ANR) is pleased to announce it has signed a Commercial Collaboration Agreement with the Pork Cooperative Research Centre (Pork CRC). The CRC will provide Anatara with services to locate key clinical trial sites and ongoing test sites, assist with the APVMA approval of its lead therapy, DetachTM, and promote the results of these trials. Detach ™ is a non-antibiotic, natural treatment to treat and prevent diarrhoea in pigs and other livestock animals.
The current CRC (High Integrity Australian Pork) has received around $20million in federal government funding, plus $18million cash from its participants and an additional $90million from in kind contributions. The current CRC has funding until 2018-19. Active partners and participants in the CRC include the largest Australian pork producers, feed manufacturers, key government and farmer industry bodies, including the CSIRO. A list of the participants can be found on the Pork CRC website.
Anatara Chief Executive Dr Paul Schober said the formal collaboration with the CRC is a significant endorsement of the critical work the company is doing in providing pork producers worldwide with an alternative to the use of antibiotics in the livestock food chain. “The Pork CRC has become the flagship for Australian pork producers,” Dr Schober said. “The relationship opens the door for Anatara to work closely with key players in the pork industry,” he added.
Pork CRC CEO, Mr Roger Campbell said he was delighted that the CRC would have the opportunity to work alongside Anatara in removing antibiotics and other chemical additives from pork production.
“The board and management of the CRC have closely reviewed the development work Anatara are doing and we believe the company provides a safe solution to one of the key issues facing the Australian pork industry and an undertaking from the Commonwealth Government to remove antibiotics from livestock production. The CRC team and participants are very much looking forward to being a key partner in Anatara’s development plans,” he said.
More information about the Pork CRC can be found on their website: www.porkcrc.com.au.
As previously announced, a second field trial for DetachTM began in June, with the results expected in the third quarter of calendar 2015. Anatara expects DetachTM to be on sale in Australia within 12 months of lodging its regulatory approval application to the APVMA based on the pace of current progress.
For more information please contact:
General inquiries
Dr Paul Schober
CEO, Anatara Lifesciences
+61 412 026 657
pschober@anataralifesciences.com
Media inquiries
Gavin Lower
Buchan Consulting
03 8866 1215
glower@buchanwe.com.au
Dr Mel Bridges
Chairman
+61413051600 melbridges@parmacorporation.com
About Anatara Lifesciences
Anatara Lifesciences is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach™ is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.
Help employers find you! Check out all the jobs and post your resume.
